• AHA seeks meeting with HHS on 340B repayments

    The American Hospital Association sent a letter to HHS on Feb. 1 requesting a meeting in a "sincere attempt to accelerate the regulatory process" of 340B repayments after years of wading through litigation. 
  • 5 reactions to Paxlovid's tweaked authorization

    Some healthcare experts and leaders expressed confusion about the FDA's decision to remove the need for a positive COVID-19 test before Paxlovid or Lagevrio can be prescribed. 
  • Experts worry Merck COVID-19 pill may give rise to new mutations

    A new preprint study found that Merck's COVID-19 pill, Lagevrio (molnupiravir), creates new mutations of the virus in some patients who take the drug, validating concerns scientists had warned about before it was authorized at the end of 2021, Bloomberg reported Feb. 1. 
  • 21st drugmaker curbs 340B drug discounts, nonprofit says

    Two more pharmaceutical companies plan to restrict 340B drug discounts to community pharmacies, nonprofit organization 340B Health said Feb. 1. 
  • Paxlovid, Lagevrio prescriptions no longer need a positive COVID-19 test

    The FDA altered its emergency use authorizations on Paxlovid and Lagevrio, two COVID-19 treatments, on Feb. 1 to revoke a requirement for a positive COVID-19 test before a provider can prescribe them. 
  • GoodRx might pay $1.5M for sharing patient data

    GoodRx Holdings illegally shared patient data to advertise on Facebook and Google, the Federal Trade Commission said Feb. 1, and the Justice Department filed a first-of-its-kind proposed order totaling $1.5 million against the prescription savings provider.
  • 'The workload remains,' APhA says on CVS, Walmart pruning pharmacy hours

    With CVS and Walmart planning to reduce pharmacy operating hours at most of their locations, pharmacists will have too much work and not enough time, the American Pharmacists Association said Jan. 30. 
  • U of Georgia develops fungal vaccine for 80% of infections

    A vaccine candidate developed by University of Georgia researchers could protect against more than 80 percent of fungal infections as antifungal drug resistance grows. 
  • Nearly 1K drug prices rose in January

    So far in 2023, pharmaceutical companies have raised prices on 988 brand-name drugs for an average 5 percent wholesale acquisition cost increase, according to 46brooklyn Research, a nonprofit that tracks drug pricing data. 
  • What the PHE's imminent end means for pharmacists

    With the nation's COVID-19 public health emergency directive set to end in May, the pharmacy industry will see at least five changes, according to the American Society of Health-System Pharmacists. 
  • 1st Humira biosimilar enters market with two prices

    Six years after regulators approved Amjevita, a biosimilar to the nation's most lucrative drug, Humira, Amgen's drug jumped on the U.S. market Jan. 31 with two list prices.
  • Civica picks insulin injector supplier

    Civica has selected Ypsomed AG as its manufacturer and supplier of insulin dosing injector pens.
  • 340B pharmacy case ruled in favor of drugmakers

    A federal appeals court ruled in favor of three drugmakers Jan. 30 in a case over requirements of whether they should give 340B drug pricing discounts to contract pharmacies. 
  • Humira's $114B monopoly to fall in February: 4 notes

    Humira, AbbVie's anti-inflammatory drug that has dozens of patents and $114 billion in U.S. sales, has a tight grasp on its market. That's soon to change, The New York Times reported Jan. 28. 
  • Sen. Warren asks FTC to probe two pharma acquisitions

    Sen. Elizabeth Warren penned a letter Jan. 25 asking the Federal Trade Commission to "closely scrutinize" two proposed pharma deals: Amgen and Horizon Therapeutics, and Indivior and Opiant. 
  • CVS, Walmart to cut hours at most pharmacies in March

    Two national chains will reduce operation hours at their pharmacies this spring, The Wall Street Journal reported Jan. 27. 
  • FDA yanks Evusheld's authorization

    On Jan. 26, the FDA revoked its emergency use authorization for Evusheld, a monoclonal antibody authorized to treat COVID-19, after finding it's ineffective against about 90 percent of circulating variants. 
  • Bergen New Bridge is first in NJ to Launch New Prescription Drug Program

    RescriptionTM aims to dramatically reduce the cost of prescription drugs for the state’s employers and their employees
  • Sinai Chicago joins CVS' equity workforce initiative

    Sinai Chicago, which represents Mount Sinai Hospital, Holy Cross Hospital, Sinai Children's Hospital and other medical organizations, partnered with CVS Health Jan. 26 to join the latter's Community Equity Alliance. 
  • FDA advisers recommend 1st Candida treatment in over a decade

    The FDA's advisory committee on antimicrobial drugs on Jan. 25 recommended rezafungin be approved to treat candidemia and invasive candidiasis in adults with limited or no alternative treatment option.

Featured Whitepapers

Featured Webinars